Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (GHSG-AFM13)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02321592
Recruitment Status : Completed
First Posted : December 22, 2014
Last Update Posted : November 13, 2020
Affimed GmbH
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Prof. Dr. Andreas Engert, University of Cologne

Brief Summary:

The study is designed

  • to demonstrate efficacy of AFM13 with an optimized treatment schedule
  • to decide whether AFM13 warrants further investigation in a phase III clinical trial

Condition or disease Intervention/treatment Phase
Hodgkin Lymphoma Drug: AFM13 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Actual Study Start Date : May 2015
Actual Primary Completion Date : November 2019
Actual Study Completion Date : July 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Arm A

AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 8 consecutive weeks.

Arm A ist closed.

Drug: AFM13
Active Comparator: Arm B

AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 2 consecutive weeks followed by a weekly appication 6 consecutive weeks.

Arm B is closed.

Drug: AFM13
Active Comparator: Arm C
AFM13 is administered for five consecutive days a week as continuous infusion for 8 consecutive weeks
Drug: AFM13

Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: at week 11 ]

Secondary Outcome Measures :
  1. Remission status based on CT/MRI and PET-CT [ Time Frame: 3 weeks after end of treatment ]
  2. Progression Free Survival (PFS) [ Time Frame: 2 years ]
  3. Overall Survival (OS) [ Time Frame: 2 years ]
  4. Adverse events (AEs) including acute treatment-associated toxicities [ Time Frame: 2 years ]
  5. Quality of Life (QoL)-score [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with diagnosis of classical HL reconfirmed by histopathology and relapsed or refractory disease after standard therapy including brentuximab vedotin and anti-PD1 or PD-L1 antibodies
  • Age: 18 years or older (both genders)
  • ECOG performance status ≤2
  • Life expectancy >3 months
  • Measurable site of disease with ≥ 1.5cm diameter which is evaluable by CT/MRI and FDG-avid by PET
  • Completion of, if applicable, radiotherapy, chemotherapy, antibodies and immunoconjugates including brentuximab vedotin and/or another investigational drug which could interact with this trial not less than 4 weeks (or 5 half-lifes of the drug, whatever occurs later) prior to first dose of study drug
  • Completion of, if applicable, an autologous stem cell transplantation (ASCT) at least 3 months prior tofirst dose of study drug
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care

Exclusion Criteria:

  • Any significant diseases (other than HL) or clinically significant findings including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the subject from participation in the study such as

    • unstable angina pectoris, symptomatic congestive heart failure (NYHA II, III, IV), myocardial infarction ≤ 6 months prior to first study drug, uncontrolled cardiac arrhythmia, cerebrovascular accidents ≤ 6 months before study drug start
    • severely impaired lung function as defined by spirometry (FEV1) and DLCO (diffusing capacity of the lung for carbon monoxide) that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
    • Liver disease as indicated by AST >3 ULN (> 5 ULN if liver involvement is present)
    • any severe or uncontrolled other disease which might increase the risk associated with study participation or study drug administration and impair the ability to evaluate the patient or for the patient to complete the study
  • Major organ dysfunction (except for HL-related reduced values e.g. in case of bone marrow or organ infiltration) as indicated by

    • Absolute Neutrophil Count (ANC) ≤1.5 x 109/l
    • Platelets <75 x 109/l
    • Hemoglobin level ≤9.0 g/dl (may be maintained by transfusions)
    • Total bilirubin >2 ULN (if >2 ULN direct bilirubin is required and should be ≤1.5 x ULN); Alkaline Phosphatase >3 ULN, AST or ALT ≥3 ULN (unless due to Hodgkin Lymphoma or diagnosed Gilbert´s Syndrome)
    • Blood creatinine level >2.0 mg/dl
  • History of a previous malignancy ≤3 years prior to first dose of study drug except basal or squamous cell carcinoma of the skin, cervical carcinoma in situ or completely resected melanoma in stage TNMpT1
  • Patients with a history of HIV seropositivity, chronic active hepatitis, or another uncontrolled active infection within 4 weeks prior to first dose of study drug
  • Patients with evidence of current central nervous system (CNS) involvement
  • Prior allogeneic stem cell transplantation (SCT)
  • Patients receiving systemic corticosteroid treatment > 10 mg daily prednisone equivalents or other chronic systemic immunosuppressive agents within 2 weeks prior to first dose of study drug or during study treatment
  • Major surgery within 4 weeks prior to first dose of study drug
  • Known hypersensitivity to recombinant proteins or any excipient in the drug formulation
  • General intolerance of any protocol medication including obligatory concomitant medication
  • Pregnant or nursing women or women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 3 months thereafter. Male patients not willing to ensure that during the study and at least 3 months thereafter no fathering takes place
  • Patient´s lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes correspondingly
  • Patients unwilling to comply with the protocol
  • Patients who have a relationship of dependence or employer-employee relationship to the sponsor or the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02321592

Layout table for location information
1st Department of Medicine, Cologne University Hospital
Cologne, Germany
Sponsors and Collaborators
University of Cologne
Affimed GmbH
The Leukemia and Lymphoma Society
Layout table for investigator information
Principal Investigator: Andreas Engert, Prof. University Hospital of Cologne
Layout table for additonal information
Responsible Party: Prof. Dr. Andreas Engert, Prof., University of Cologne Identifier: NCT02321592    
Other Study ID Numbers: Uni-Koeln-1754
2014-004036-19 ( EudraCT Number )
First Posted: December 22, 2014    Key Record Dates
Last Update Posted: November 13, 2020
Last Verified: November 2020
Keywords provided by Prof. Dr. Andreas Engert, University of Cologne:
Hodgkin Lymphoma
Natural Killer Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases